The “Free by 5” Campaign for Universal, Free Antiretroviral Therapy by Whiteside, Alan & Lee, Sabrina
PLoS Medicine  |  www.plosmedicine.org 0724
Health in Action
Open access, freely available online
August 2005  |  Volume 2  |  Issue 8  |  e227
T
he Free by 5 declaration 
(http:⁄⁄www.ukzn.ac.za/heard/
freeby5/freeby5.htm), launched 
in November 2004, is a campaign to 
achieve free access for all individuals 
with HIV to a comprehensive 
minimum medical package including 
antiretroviral treatment (ART). The 
declaration was developed in response 
to the World Health Organization 
(WHO) and the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) 
“3 by 5” strategy, which aims to scale 
up access to ART to ensure that 3 
million people have access to ART by 
the end of 2005 [1]. We believe that 
the declaration made an important 
contribution to the debate on provision 
of ART in resource-poor settings. 
A number of debates still surround 
the 3 by 5 strategy, including how it 
will be operationalised and funded [1]. 
Questions remain over how the poorest 
and most vulnerable groups can be 
reached and how a suitable level of 
adherence to the drugs can be achieved 
to avoid drug resistance [2]. 
The Problem with User Fees
Currently, fewer than 8% of people 
living with HIV/AIDS in Africa are on 
ART [3]. While user fees represent only 
one of the barriers to access to essential 
ART, the Free by 5 initiative ﬁ  rmly 
states that unless treatment is provided 
free of charge to all in developing 
countries, 3 by 5 will struggle to meet 
its ambitious target. Many countries 
still impose user fees for ART and 
associated tests, and as AIDS is an 
impoverishing disease, this means 
treatment is unaffordable for most [4]. 
We must state clearly that we 
acknowledge that providing 
treatment free of charge is not the 
only precondition for the scale-up 
of treatment programmes. In most 
developing countries, the availability 
and efﬁ  ciency of health infrastructure 
is the dominant obstacle to effective 
health care. Adequate primary 
health-care infrastructure and staff 
is fundamental to the provision of 
treatment programmes. However, we 
argue that where drugs and services 
are administered, providing treatment 
for free would assist patients to gain 
greater access to, remain adherent 
to, and avoid instability in treatment 
regimens. Simply stated, the Free by 5 
campaign maintains that user fees are 
an additional and unnecessary obstacle 
to treatment access and the efﬁ  ciency 
and equity of treatment programmes in 
the context of this major health crisis. 
Furthermore, removal of patient fees as 
a signiﬁ  cant barrier to access is realistic 
and feasible in resource-poor settings
This article outlines the Free by 5 
campaign and its objectives. It sketches 
the arguments for free treatment and 
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describes how the initiative inﬂ  uenced 
the debate surrounding HIV/AIDS 
treatment among donors, international 
institutions, non-government 
organisations, professionals in the 
ﬁ  elds of public health and economics, 
and the concerned public. 
Origins and Objectives of Free by 5
The Free by 5 initiative began as 
a challenge to one of us (Alan 
Whiteside) at a Commission on 
HIV/AIDS and Governance in Africa 
meeting in Maputo from Veronique 
Collard, an academic and activist, 
who asked, “What do economists 
believe?” This challenge led to the 
idea that a declaration, giving the 
economists’ position, could be adopted 
by the International AIDS Economics 
Network meeting in Bangkok. A ﬁ  rst 
draft was prepared and presented 
at this meeting, but the reception 
from the assembled economists was 
underwhelming. 
Despite this, we decided to press 
ahead. Veronique gave freely of her 
time in developing the initiative 
and was guided by many people, 
particularly Bernard Taverne of Institut 
de Recherche pour le Développement, 
Senegal; Alice Desclaux of University 
of Paul Cezanne, France; Gorik Ooms 
of Médecins Sans Frontières (MSF) 
in Belgium; and Alan Whiteside. We 
at HEARD contributed to the costs 
involved and provided a secretariat. 
Countless others in the ﬁ  eld gave their 
support and enthusiasm, without which 
the initiative could not have happened.
The overall goal of the initiative was 
to gather support from professionals 
and organisations to promote universal 
free access to a minimum health-
care package, including ART, for 
people with HIV. It aimed to lobby 
international institutions, including 
UNAIDS, WHO, and donors— such as 
the Global Fund, the World Bank, and 
the US President’s Emergency Plan 
for AIDS Relief—to adopt guidelines 
and actively promote the principle 
and implementation of free treatment. 
Donors were urged to pledge 
additional resources to ART through 
long-term commitments. Finally, the 
initiative sought to provide economic 
and public health evidence to inform 
the decisions of policy makers and 
governments and assist activists in their 
advocacy efforts.
What Do WHO and 3 by 5 Say 
about Free Treatment?
The Free by 5 declaration makes 
the point that the 3 by 5 strategy 
is unrealistic. Although the WHO 
seeks increased access to ART for 
all people living with HIV/AIDS, 
it does not address the costs at the 
patient level. The Free by 5 campaign 
believes that free treatment is an 
absolute prerequisite to the scale-up of 
treatment programmes and universal 
access to treatment.
Despite clear indications that 
patient fees inhibit access to treatment 
programmes, as outlined in the 
following section, the WHO strategy 
documents do not address this 
issue. Instead, the WHO treatment 
guidelines make frequent references 
to “affordability.” The WHO strategy 
published in 2003 recommended 
making antiretrovirals affordable and 
providing them free of charge to the 
poor [5]. A revision of the guidelines 
recommends providing “medication 
free of charge to those who can least 
afford treatment through subsidized 
or other ﬁ  nancing strategies” [6]. 
A 2004 Consultation Report stated 
that if “cost recovery schemes 
prove inefﬁ  cient or obstructive to 
access, free delivery to all should be 
considered” [7]. It should be noted 
that much of this debate is conﬁ  ned 
to ART. In the Free by 5 declaration, 
we recognise that treatment includes 
testing, laboratory examinations, and 
associated drugs. 
Arguments for and against 
Free Treatment
What affordability means and who 
is poor is not deﬁ  ned in these WHO 
guidelines. Deﬁ  ning the poor by 
income level is problematic in 
countries where the informal economy 
(that is, unregistered, unrecognised, 
and unsupported employment) 
dominates and income records are 
poor. 
The process of implementing 
exemptions based on income is a 
waste of scarce ﬁ  nancial and human 
resources as systems are costly to put 
in place and administer. Exemptions 
or waivers rarely reach those who are 
eligible to receive them [8]. While the 
WHO maintains that “free treatment 
would be difﬁ  cult to implement in 
many health systems” [9], the Free by 
5 declaration states that it will be easier 
and more cost-effective to provide 
treatment to all patients free of charge.
Countries set their own criteria for 
access, and these vary. In addition, 
perceptions of equity vary among and 
between governments, donors, and 
activists. These variations are difﬁ  cult 
to manage from a clinical perspective 
and prevent equity from being attained 
at a national and international level 
[10]. Existing criteria for access are 
inequitable: a ﬁ  rst-come, ﬁ  rst-served 
basis favours the rich, more educated, 
and urban people. Universal free 
treatment is necessary to achieve equity 
in access and to avoid exclusion of 
the most susceptible and vulnerable 
groups. 
The Free by 5 declaration details a 
number of arguments that have been 
made against free treatment and gives 
evidence that counter these views. 
There are claims that patients should 
pay in order to give value to treatment 
and remain adherent to the drugs. 
Studies in Senegal have shown that 
user fees inhibit patient adherence and 
cause frequent interruptions in therapy 
[11], and in Kenya user fees have led 
to the discontinuation of treatment 
and delays in health-seeking behaviour 
[12]. The negative relationship 
between end-user costs and adherence 
has also been echoed in data from 
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Uganda [13], Nigeria [14], Botswana 
[15], and the Côte d’Ivoire [16]. When 
ART must be paid for, patients are 
also more likely to misuse drugs and 
purchase them on the informal market. 
This ultimately leads to drug resistance. 
In some cases, the costs of laboratory 
tests deter people from joining 
treatment programmes. Providing 
treatment for free reduces delays in 
seeking care and improves adherence 
and may inﬂ  uence the quality of care. 
A major argument against 
free treatment is that of AIDS 
exceptionalism. In other words, why 
should AIDS be treated for free when 
others diseases are not? There are three 
simple arguments countering this view. 
First, AIDS is the worst epidemic 
humanity has ever faced, which 
has devastating long-term social, 
economic, and personal impacts and is 
a major obstacle to development. The 
exceptionalism of the disease requires 
exceptionalism in the response. At 
the UN General Assembly meeting 
on HIV/AIDS in New York, on 22 
September 2003, WHO Director 
General Jong-Wook Lee described 
the lack of ART as a global health 
emergency. Second, other diseases are 
treated free where there is a public 
health reason to do so. Third, it is 
feasible to implement free HIV/AIDS 
treatment in resource-poor settings. 
Given the nature of the AIDS epidemic, 
providing free treatment should be an 
imperative even if it can not be applied 
to all diseases or all in need.
It is argued that patient fees are 
necessary to ensure the sustainability 
of treatment programmes. However, 
in Senegal fees amount to little more 
than 10% of the cost of drugs [11]. 
Patient contributions do not cover 
other costs such as staff, training, 
and social services. Sustainability 
can be achieved only through long-
term commitments from donors and 
governments. The WHO and UNAIDS 
estimate that the total cost of providing 
treatment through the 3 by 5 initiative 
for 2005 is $3.8 billion, and this will 
increase to $6.7 billion in 2007 [17]. 
The contribution made by fee-paying 
patients is negligible. In Ghana, for 
instance, user fees amount to no more 
than a tiny fraction of the Ministry 
of Health aggregate budget [18]. 
Therefore, providing treatment for free 
will have virtually no effect on global 
resource needs. Signiﬁ  cant resources 
still need to be mobilised. 
The Impact of Free by 5
The Free by 5 declaration, which 
is available in French, English, 
and Spanish, was disseminated 
worldwide through global MSF ofﬁ  ces, 
universities, schools of public health, 
and NGO networks. It was signed 
by more than 600 people, many of 
whom are respected public health 
professionals, economists, policy 
makers, and key activists. Some of the 
inﬂ  uential signatories are shown in Box 
1. The declaration was also signed by 
a number of organisations, shown in 
Box 2. 
The initiative sparked extensive 
debate among Internet-based 
development and public health fora. It 
culminated in a media release, which 
was disseminated widely among the 
global press. The initiative was picked 
up by British, French, South African, 
and Kenyan national newspapers as 
well as the UN IRIN Plus News. It was 
also featured on a number of Web sites.
It is difﬁ  cult to asses the impact 
of the declaration over such a short 
time frame. After the media launch, 
the declaration and list of signatures 
were sent to UNAIDS, WHO, and 
the World Bank. We urged these 
organisations to give unambiguous 
support to the implementation of 
free treatment and take a lead in 
raising awareness about the issue. We 
encouraged all governmental and non-
governmental actors to adopt universal 
free treatment and actively promote 
its implementation. We asked that the 
issue be included on the agenda of 
technical meetings and political forums 
planned in the framework of the 3 by 
5 initiative, and reﬂ  ected clearly in all 
WHO/UNAIDS guidelines. 
At the very least, the Free by 5 
declaration publicised the issue and 
the importance of universal free access 
to treatment and created a debate 
surrounding free treatment in public 
health, health economics, and human 
rights circles throughout the world. It 
is an issue that has been placed on the 
international agenda for discussion. 
For instance, the Free by 5 
campaign played a role in inspiring 
the recent WHO/UNAIDS/World 
Bank meeting entitled “Ensuring 
universal access: User fees and free 
care polices in the context of HIV 
treatment” (21–23 March 2005). 
The meeting acknowledged that “for 
many individuals in poor countries, 
affordability poses an insurmountable 
obstacle” that depresses uptake of 
AIDS treatment programmes and 
decreases adherence of those enrolled. 
The meeting also noted that user 
fees contribute very little to overall 
sustainability and that if AIDS care and 
treatment programmes are to be scaled 
up, a broad shift to other ﬁ  nancing 
models is required [19]. 
Conclusion
There are many lessons from this 
initiative, but two are particularly 
important. The ﬁ  rst is that a good 
idea can, with the right support, be 
turned into something concrete. The 
second is that goodwill and good sense 
are as important as money in shaping 
the policy environment. It was a small 
initiative with a big impact. We hope 
that eventually we will see the fruits 
of our efforts: universal free access to 
ART to all who need them. We feel 
privileged to have been part of this 
important campaign.  
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